Chemotherapy News and Research

Latest Chemotherapy News and Research

Micromet's blinatumomab demonstrates potential to change outcome for patients with ALL

Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab.

15 Jun 2010

2,300 researchers under one roof at American Society of Echocardiography 21st Annual Scientific Sessions

Research released today at the American Society of Echocardiography (ASE) 21st Annual Scientific Sessions unveiled findings that will have a significant impact on the diagnosis and treatment of heart disease and the application of echocardiography in the future.

15 Jun 2010

MRSA survivors unite across the globe to raise awareness and educate public on prevention

MRSA Survivors Network with MRSA survivors, family members and other victims of healthcare-acquired infections unite across the globe and on World MRSA Day, October 2, 2010 in a grassroots movement to raise awareness and push for more mandated reporting of infections, MRSA screening laws, funds to raise awareness and educate the public on prevention, which will save lives.

15 Jun 2010

Updated Phase 1 trial results of blinatumomab in patients with relapsed NHL presented at EHA 2010

Micromet, Inc. today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma. A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.

14 Jun 2010

Study confirms impact of febrile neutropenia on chemotherapy delivery in NHL

Data presented at the 15th European Hematology Association (EHA) congress in Barcelona, highlights the impact of febrile neutropenia (FN) on chemotherapy delivery in non-Hodgkin lymphoma (NHL) patients. The IMPACT NHL study showed that unplanned hospitalisations, delays in chemotherapy and reductions of chemotherapy dose leading to suboptimal relative dose intensity (RDI) of chemotherapy were more frequent in patients who experienced FN than those who did not.

14 Jun 2010

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving overall survival in the first-line setting.

14 Jun 2010

Australian rainforests may provide potential cancer cure

Queensland scientists have discovered a drug to cure cancer that has effectively worked in animals and is to be tried on humans in the next phase of trials. This drug is plant-derived and is called EBC-46 for trial purposes. The plant from which it is obtained is found in the Australian tropical rainforest. The drug has shown to reduce inoperable tumors in 150 dogs, cats and horses and a ferret to a significant extent. The drug was developed over the past six years from the seed of a rainforest plant found in the Atherton Tablelands. Scientists had cultivated their own plantation of the plant since forming the company QBiotics Limited in 2004.

14 Jun 2010

PAF launches CINV CareLine to assist patients with cancer, CINV

Patient Advocate Foundation – a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases – is pleased to announce that it has launched a new program, the CINV CareLine.

11 Jun 2010

FDA grants orphan drug designation for ICT-107

ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.

11 Jun 2010

Eribulin mesylate drug may help extend lives of women with advanced breast cancer

A new drug, based on a natural extract from sea sponge, may help to extend the lives of women with advanced breast cancer, UK scientists have found. A research team at the University of Leeds and St James's Institute of Oncology led an international trial of the new chemotherapy drug, eribulin mesylate.

11 Jun 2010

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.

11 Jun 2010

Delcath Systems to host conference call to update shareholders about recent progress

Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology will host a conference call to discuss recent corporate developments on Tuesday, June 15, 2010 at 4:30 p.m., Eastern. Eamonn P. Hobbs, the Company's President and CEO, David McDonald, CFO, and Krishna Kandarpa, MD, Chief Medical Officer, will be on hand during the call and webcast.

11 Jun 2010

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Abraxis BioScience, Inc. presented trial design information from its ongoing phase 3 registration trial of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), in melanoma, an aggressive form of skin cancer that affects more than 68,000 people in the U.S. each year.

11 Jun 2010

CTT's Calmare Pain Therapy Treatment shows promise against CIPN

Competitive Technologies, Inc. today announced the presentation of results from a study that shows the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy using CTT's Calmare Pain Therapy Treatment. A three-hour discussion led by principal investigator, Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, at the American Society of Clinical Oncology Annual Meeting, cited results of the study.

11 Jun 2010

$Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL$

Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL

Cell Therapeutics, Inc. today reported exploratory analyses of the data at study completion from the Company's pivotal PIX301 trial of Pixuvri, the first randomized controlled trial in patients with relapsed or refractory, aggressive non-Hodgkin's lymphoma.

11 Jun 2010

Widely used cancer drug bevacizumab can lead to proteinuria, kidney damage: Study

The widely used cancer drug bevacizumab may cause severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The results suggest that physicians should monitor patients' kidney health when prescribing this angiogenesis inhibitor.

11 Jun 2010

UAB researchers win grant to study metastasis of dead cancer cells

Researchers with the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center and UAB Department of Chemistry have won an $805,000 grant from the U.S. Department of Defense Breast Cancer Research Program to study whether dead cancer cells left over after treatment encourage cancer's spread to other parts of the body.

11 Jun 2010

Programme on surgical and medical treatment strategies for cancer

The 5th ESU Master class on medical treatment for urological cancer is organised by the European School of Urology (ESU) on 25-27 June 2010 at the Barcel- Hotel Sants in Barcelona, Spain.

11 Jun 2010

Older breast cancer women in Scotland do not receive same level of treatment as younger patients

Older women in Scotland who have been diagnosed with breast cancer do not always receive the same level of treatment as younger patients, the charity Breakthrough Breast Cancer has said. According to the charity, Scottish women over the age of 80 are 40 times less likely to be offered surgery, chemotherapy and radiotherapy for breast cancer.

11 Jun 2010

Bevacizumab increases risk for proteinuria in cancer patients

Cancer patients treated with the chemotherapy agent bevacizumab (Avastin) may be at an increased risk of severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment. This conclusion stems from a study of more than 12,000 patients by Shenhong Wu, M.D., Ph.D., Principal Investigator, and colleagues at Stony Brook University Medical Center. Their findings are reported in online June 10 in the Journal of the American Society Nephrology (JASN).

11 Jun 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Micromet's blinatumomab demonstrates potential to change outcome for patients with ALL

2,300 researchers under one roof at American Society of Echocardiography 21st Annual Scientific Sessions

MRSA survivors unite across the globe to raise awareness and educate public on prevention

Updated Phase 1 trial results of blinatumomab in patients with relapsed NHL presented at EHA 2010

Study confirms impact of febrile neutropenia on chemotherapy delivery in NHL

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

Australian rainforests may provide potential cancer cure

PAF launches CINV CareLine to assist patients with cancer, CINV

FDA grants orphan drug designation for ICT-107

Eribulin mesylate drug may help extend lives of women with advanced breast cancer

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

Delcath Systems to host conference call to update shareholders about recent progress

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

CTT's Calmare Pain Therapy Treatment shows promise against CIPN

Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL

Widely used cancer drug bevacizumab can lead to proteinuria, kidney damage: Study

UAB researchers win grant to study metastasis of dead cancer cells

Programme on surgical and medical treatment strategies for cancer

Older breast cancer women in Scotland do not receive same level of treatment as younger patients

Bevacizumab increases risk for proteinuria in cancer patients

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in